Reply to the Letter to the Editor 'Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up")' by Cellini et al

Affiliations

¹ Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
² Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Free article

Comment

R Obermannová et al. Ann Oncol. 2023 Jun.

Free article

. 2023 Jun;34(6):554-555.

doi: 10.1016/j.annonc.2023.03.004. Epub 2023 May 5.

¹ Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
² Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

No abstract available

Comment on

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Obermannová R, et al. Ann Oncol. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29. Ann Oncol. 2022. PMID: 35914638 No abstract available.
Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to 'Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up').
Cellini F, Manfrida S, Gambacorta MA, Valentini V. Cellini F, et al. Ann Oncol. 2023 Jun;34(6):553-554. doi: 10.1016/j.annonc.2023.03.003. Epub 2023 Mar 23. Ann Oncol. 2023. PMID: 36965575 No abstract available.